Switching to extended half‐life products in Canada – preliminary data

1 Mohri H. Acquired von Willebrand syndrome: features and management. Am J Hematol 2006; 81: 616–23. 2 Mital A. Acquired vonWillebrand syndrome. Adv Clin ExpMed 2016; 25: 1337–44. 3 Federici AB, Rand JH, Mannucci PM. Acquired von Willebrand syndrome : an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders. Ann Hematol 2001; 2: 358–63. 4 Mayerhofer M, Haushofer A, Kyrle PA et al. Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein. Eur J Clin Invest 2009; 39: 833–6. 5 Perez-Rodriguez A, Pinto JC, Loures E et al. Acquired von Willebrand syndrome and mitral valve prosthesis leakage. A pilot study. Eur J Haematol 2011; 87: 448–56. 6 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117: 6777–85. 7 Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost 2008; 6: 565–8. 8 Sucker C, Michiels JJ, Zotz RB. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies. Acta Haematol 2009; 121: 177–82. 9 Sadler JE, Budde U, Eikenboom JCJ et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103–14. 10 Federici AB, Mannucci PM, Castaman G et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B : a cohort study of 67 patients. Blood 2011; 113: 526–34.